SMSLIFE Stock View

SMS Lifesciences India Ltd

SMSLIFE Stock View

(NSE)

Trade

₹ 518.9

-3.65 | -0.70

Market Cap ₹( Cr.)
1,564.70

Proj. P/E (x)

Proj. P/BV (x)

Proj. ROE (%)

Proj EV / EBITDA (x)
--

Proj. Revenue ( Cr.)

Last Updated On.
03-Dec-2023

 

Copy Link

SMS Lifesciences India Limited is an India-based company that is engaged in the business of manufacturing of active pharma ingredients (API) and their intermediates. The Company's API products include Ranitidine Hydrochloride (Form-2) USP / Ph.Eur / IP, Famotidine USP / Ph.Eur / IP, Sildenafil Citrate USP / Ph.Eur / IP, Allopurinol USP / EP / IP, Ropivacaine Hydrochloride USP / EP / IP, Dapsone USP/ EP /BP, Sibutramine Hydrochloride USP, Itraconazole USP / Ph.Eur, Fosphenytoin Sodium USP, Domperidone / Domperidone Maleate EP / IP, Brinzolamide, Tiagabine, Fosaprepitant and Albendazole, among others. The Company's manufacturing facilities are located at Kazipally and Jeedimetla, and its research and development center at Sanath Nagar in Hyderabad. The Company's wholly owned subsidiary is Mahi Drugs Private limited.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data